Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations.
J Addict Dis
; 41(1): 53-63, 2023.
Article
en En
| MEDLINE
| ID: mdl-35356868
ABSTRACT
BACKGROUND:
There is limited knowledge on the causes of large variations in serum methadone concentrations and dose requirements.OBJECTIVES:
We investigated the impact of the degree of liver fibrosis on dose-adjusted steady-state serum methadone concentrations.METHODS:
We assessed the clinical and laboratory data of 155 Norwegian patients with opioid use disorder undergoing methadone maintenance treatment in outpatient clinics in the period 2016-2020. A possible association between the degree of liver fibrosis and dose-adjusted serum methadone concentration was explored using a linear mixed-model analysis.RESULTS:
When adjusted for age, gender, body mass index, and genotypes of CYP2B6 and CYP3A5, the concentration-to-dose ratio of methadone did not increase among the participants with liver fibrosis (Coefficient 0.70; 95% CI -2.16, 3.57; P 0.631), even among those with advanced cirrhosis (-0.50; -4.59, 3.59; 0.810).CONCLUSIONS:
Although no correlation was found between the degree of liver stiffness and dose-adjusted serum methadone concentration, close clinical monitoring should be considered, especially among patients with advanced cirrhosis. Still, serum methadone measurements can be considered a supplement to clinical assessments, taking into account intra-individual variations.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Metadona
/
Trastornos Relacionados con Opioides
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
J Addict Dis
Asunto de la revista:
TRANSTORNOS RELACIONADOS COM SUBSTANCIAS
Año:
2023
Tipo del documento:
Article
País de afiliación:
Noruega